Venomics AI Raises $2.7 Million to Turn Animal Venom Into Drugs

What the money will fund

The capital will go towards expanding the Venom Atlas, a molecular dataset of venom-derived compounds, and strengthening the startup's AI and laboratory screening capabilities. Venomics AI also plans to grow its team across venom biology, computational science and drug discovery, and to support the validation and optimisation of promising molecules.

Why venom

Animal venoms contain complex molecules that have evolved over millions of years to act on specific biological targets, and some have already inspired medicines. Yet much of the molecular diversity across venomous species remains unexplored, which the company sees as an opening for drug discovery.

Its platform uses molecular sequencing and venom biology to map that diversity in the Venom Atlas. AI then prioritises promising candidates, and functional laboratory screening tests those predictions. "Animal venoms represent one of nature's richest yet least explored sources of potential medicines," Sunagar said.

Wider backdrop

Based on IBEF data, India's bioeconomy is on track to reach $300 billion by 2030, and the country is home to more than 11,000 biotech startups. In Budget 2027, finance minister Nirmala Sitharaman announced a 'Biopharma SHAKTI' scheme with an outlay of ₹10,000 crore.

Investor interest is also rising. Earlier this year Cellogen Therapeutics secured ₹20 crore from Kotak Alternate Asset Managers, while StrainX Bioworks raised $13 million in a round led by Prime Venture Partners and Leo Capital.